BRIDGEWATER, NJ - Tharimmune, Inc. (NASDAQ:THAR), a biotechnology firm focusing on inflammation and immunology therapies, announced it has secured approximately $2.08 million through a private placement. The transaction includes the sale of 659,545 shares of common stock, or equivalents, and warrants for an additional 329,771 shares, priced at $3.16 per share and warrant, respectively.
The warrants, with an exercise price of $3.09, will become exercisable six months following their issuance and will expire after five and a half years. The expected closing date for the offering is June 21, 2024, contingent on customary closing conditions.
President Street Global is serving as the exclusive placement agent for the offering, which was led by SDS Capital Group, Gravitas Capital, and other private investors specializing in biotechnology.
Tharimmune plans to allocate the net proceeds from this placement to further clinical development and for working capital purposes, with a particular focus on advancing its TH104 development program. TH104 is a therapeutic candidate aimed at treating chronic pruritus in primary biliary cholangitis, a rare liver disease.
Tharimmune's TH104 is a buccal film embedded with nalmefene designed to easily adhere to the inside of the mouth, targeting both the µ-opioid and kappa opioid receptors involved in the body's itch circuitry. The company's pipeline also includes novel multi-specific antibodies for multiple solid tumors.
This announcement is based on a press release statement.
In other recent news, Tharimmune, Inc. has seen a series of developments. The biopharmaceutical firm has received positive feedback from the FDA for its Phase 2 clinical trial plan for TH104, a treatment for severe itchiness in patients with primary biliary cholangitis.
Tharimmune has integrated FDA suggestions into the trial protocol and expects to launch the study in 2024. The company also reported promising Phase 1 trial results for TH104, indicating its safety and comparable pharmacokinetic profile with intravenous delivery.
Tharimmune has announced a 1-for-15 reverse stock split, aimed at meeting Nasdaq's minimum bid price requirement. In partnership news, the company has entered an exclusive licensing agreement with Washington University in St. Louis to develop and commercialize a series of antibodies targeting the human HER2 protein.
Lastly, Tharimmune has established a Scientific Advisory Board composed of experts in immunology, liver diseases, and antibody-drug conjugates. ThinkEquity initiated coverage on Tharimmune with a Buy rating, highlighting the projected revenue potential for TH104, the company's lead product, ranging from $350 million to $500 million from PBC alone.
These are among the recent developments for Tharimmune.
InvestingPro Insights
Tharimmune, Inc. (NASDAQ:THAR) has taken proactive steps to strengthen its financial position through a private placement, raising capital to fund its clinical development programs. As the company prepares to advance its TH104 development program, investors are closely monitoring its performance metrics and market sentiment.
InvestingPro data shows a challenging financial landscape for Tharimmune, with a market capitalization of just $2.33 million. The company's Price to Earnings (P/E) ratio stands at -0.16, reflecting market skepticism about its profitability in the near term. Moreover, the Price / Book ratio as of the last twelve months is low at 0.33, which could indicate that the stock is undervalued relative to its assets, or that investors are not confident in the company’s ability to generate future profits.
Recent price movements have been particularly volatile for Tharimmune, with a 1-month price total return of -47.43% and a 6-month price total return of -60.86%. This underscores the market's reaction to the company’s performance and the inherent risks in the biotechnology sector. The stock's current price is a mere 1.82% of its 52-week high, suggesting a significant downturn over the past year.
Among the InvestingPro Tips, two are particularly noteworthy for potential investors. Tharimmune holds more cash than debt on its balance sheet, which is a positive sign of financial stability. Additionally, the stock's Relative Strength Index (RSI) suggests it is in oversold territory, which could indicate a potential rebound if market conditions improve and the company's developments meet milestones.
Investors seeking to delve deeper into Tharimmune's financials and market performance can find a wealth of additional insights on InvestingPro. There are 14 more InvestingPro Tips available, which could help in making a more informed investment decision. For those interested, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.